Canagliflozin and cardiovascular and renal events in type 2 diabetes - The New England Journal of Medicine - 2017

Brief Summary:

Among patients with T2DM at high risk for CV events, canagliflozin had a lower risk of cardiovascular events and reduced the rate of renal decline and heart failure hospitalization compared to those who received placebo but a greater risk of amputation.